The main strategies for tuning BODIPY fluorophores into photosensitizers

Abstract

Photodynamic therapy (PDT) is a minimally invasive technique for the treatment of target malignant tumors via the generation of highly reactive singlet oxygen species. PDT treatment of cancer/tumor tissues greatly relies on the development of suitable stable, highly specific and efficient photosensitizers. BODIPY (Boron dipyrromethene) derivatives, as a class of well-developed, versatile fluorescent dyes, has emerged as a new class of PDT agents over the past decade. Many elegant strategies have been developed to enhance the singlet oxygen generation efficiency and the cancer/tumor cell selectivity of BODIPY-based photosensitizers to improve the therapeutic outcomes as well as to minimize the side effects. Many of the currently reported BODIPY-based photosensitizers are valuable dual imaging and therapeutic agents, which can efficiently generate singlet oxygen for PDT and emit fluorescence for in vivo imaging. Although the currently approved PDT agents used for clinical trials do not feature BODIPYs, this situation is expected to change. In this review, we provide an overview of the various strategies that have been used to improve the singlet oxygen generation efficiency for tuning BODIPY fluorophores into photosensitizers and dual imaging/therapeutic agents. Their photophysical properties and photocytotoxic activity including the absorption/emission wavelengths, the singlet oxygen generation efficiency ([Formula: see text] and the half maximal inhibitory concentration [Formula: see text] of these currently reported photosensitizers are summarized. We believe these newly developed BODIPY-based photosensitizers will broaden current concepts of strategies for PDT agent design, and promise to make an important contribution to the diagnosis and therapeutics for the treatment of cancer.